The most common side effects of Dupixent (dupilumab) are injection-site reactions and conjunctivitis, which together account for the majority of complaints reported in clinical trials and real-world use. Across age groups, the drug is generally well tolerated, with serious adverse events occurring less often in treated patients than in those receiving placebo. But “well tolerated” does not mean side-effect-free, and some reactions, particularly eye-related ones, catch people off guard because they seem unrelated to the skin or lung conditions the drug treats.
How Dupixent Works and Why That Matters for Side Effects
Dupixent is a monoclonal antibody that blocks the interleukin-4 receptor alpha subunit, shutting down signaling by two inflammatory molecules, IL-4 and IL-13, that drive what immunologists call type 2 inflammation.1PubMed Central. Dupilumab: Mechanism of action, clinical, and translational science That mechanism is central to why the drug works in conditions like atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. It also explains most of its side effects: IL-4 and IL-13 do things outside the skin and lungs, so blocking them can have unintended consequences in the eyes, the blood, and occasionally the joints. Understanding this connection helps make sense of reactions that otherwise seem random.
Injection-Site Reactions
Since Dupixent is a subcutaneous injection given every two weeks (or weekly for some dosing schedules), some irritation at the injection site is the most straightforward side effect. In pooled clinical trial data, injection-site reactions showed up in roughly 12% of patients on the standard every-two-week schedule, compared to about 7% on placebo.2JAAD Case Reports. Ulcerative injection-site reaction associated with dupilumab therapy The weekly dosing schedule pushes that higher, to about 17%. In a real-world study comparing Dupixent to another biologic (tralokinumab), the reactions were almost always mild and did not cause anyone to stop treatment.3PubMed. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
Most injection-site reactions look like redness, swelling, or mild itching that resolves within a few days. Occasionally, though, they can be more unusual. Delayed reactions at a previous injection site have been documented, likely related to polysorbate excipients in the formulation rather than the drug itself.4PubMed Central. Delayed local reaction at a previous injection site reaction with dupilumab If you notice a bump or redness at an old injection spot weeks later, that is likely the explanation. Rotating injection sites and letting the prefilled syringe or pen warm to room temperature before injecting can reduce the frequency and intensity of these reactions.
Eye Problems Are the Most Distinctive Side Effect
Conjunctivitis is the side effect most uniquely associated with Dupixent, and it catches many patients by surprise. In clinical trials for atopic dermatitis, the incidence ranged from roughly 4% to 31% depending on the study, far higher than what was seen with placebo.5PubMed Central. Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events–Incidence, Etiology, and Management A real-world prospective study found that about 35% of patients experienced some form of ocular adverse event, mostly dry eye disease with superficial punctate keratitis.6PubMed. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study Most cases were mild to moderate, and only a small number of patients needed to stop the drug because of their eyes. A long-term real-world chart review from a single center found conjunctivitis in about 16% of patients and eye dryness in about 8%.7Wiley Online Library. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above
The eye issues go beyond simple pink eye. Blepharitis (inflammation of the eyelids), keratitis (inflammation of the cornea), and in rare cases corneal ulcers and cicatricial (scarring) conjunctivitis have been reported, and clinicians increasingly recognize these as underestimated.8PubMed Central. Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature If you are on Dupixent and notice persistent eye redness, itching, tearing, or a gritty sensation, do not write it off as allergies. Mention it to your prescriber, because early management usually keeps the problem from escalating.
Why Dupixent Affects the Eyes
The leading explanation centers on goblet cells, which are mucus-producing cells in the lining of the eye. IL-13, one of the two signals Dupixent blocks, helps maintain those goblet cells. A study examining biopsies from patients who developed conjunctivitis on Dupixent found a marked scarcity of goblet cells along with inflammatory infiltrates in the conjunctiva.9British Journal of Dermatology. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis Without enough goblet cells, mucin production drops, the tear film becomes unstable, and the surface of the eye becomes prone to irritation and inflammation. All the patients in that study reported dry eyes, which then progressed to irritative conjunctivitis in some.
One important pattern: eye side effects occur far more often in patients being treated for atopic dermatitis than in those using Dupixent for asthma, nasal polyps, or eosinophilic esophagitis.10PubMed. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review The reason is not entirely clear, but it likely relates to the pre-existing ocular surface disease that many people with atopic dermatitis already have. If you are taking Dupixent for asthma and have no history of eczema, your risk of eye problems is substantially lower.
Managing Eye Side Effects
An expert consensus panel published guidelines for handling Dupixent-related eye issues, and the overarching message is that ocular side effects should not stop you from using the drug if it is otherwise working well.11British Journal of Dermatology. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis For mild dry eye, preservative-free artificial tears are the first step. If actual conjunctivitis develops, your dermatologist should assess severity and consider whether an ophthalmology referral is needed. In most cases, the issue can be managed alongside continued Dupixent treatment. The key is not to ignore it and hope it resolves on its own, because untreated eye inflammation can progress.
Head and Neck Dermatitis
This is the paradox that frustrates patients: you start a powerful anti-eczema drug, your body clears up everywhere except your face and neck, and a new rash appears there. Dupixent-associated head and neck dermatitis (sometimes abbreviated DAHND) occurs in an estimated 4% to 10% of patients, though some real-world reports put it higher.12Nature Communications. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells It typically shows up within the first two months of treatment but can appear as late as nine months in.13PubMed Central. Recognizing Dupilumab‐Associated Head and Neck Dermatitis in Skin of Color: A Case Series In a long-term real-world chart review, it was the single most common side effect, affecting about 20% of patients.14Wiley Online Library. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above
The rash looks different from regular eczema. In a case series examining seven patients, the affected skin showed well-defined, patchy redness with less scaling than the patients’ usual flares, and biopsies revealed dilated blood vessels and a psoriasis-like pattern rather than classic eczema changes.15British Journal of Dermatology. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series Despite the rash, six of those seven patients reported high satisfaction with the drug because their eczema elsewhere was dramatically better. Topical treatments and systemic medications tried for the facial redness were largely unsuccessful, but none of the patients chose to stop Dupixent.
In patients with darker skin tones, this side effect can present differently, sometimes with violaceous (purplish) hues rather than the bright redness seen in lighter skin, making it harder to recognize.16PubMed Central. Recognizing Dupilumab‐Associated Head and Neck Dermatitis in Skin of Color: A Case Series The underlying mechanism appears to involve a shift in immune signaling: with IL-4 and IL-13 suppressed, the immune system overactivates an IL-22-driven pathway that causes the distinctive facial inflammation.17Nature Communications. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Paradoxical Psoriasis
Rare but reported, some patients develop psoriasis-like skin lesions while on Dupixent. The proposed explanation follows a similar logic to head and neck dermatitis: blocking IL-4 removes a brake on certain immune pathways. IL-4 normally helps keep Th1 and Th17 immune cells in check, and those cell types are the drivers of psoriasis. When Dupixent removes that restraint, the balance can tip toward a psoriasis-like inflammatory state in predisposed individuals.18PubMed Central. Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab This is uncommon enough that it exists mainly as case reports, but if you develop thick, silvery, well-defined plaques that do not look like your usual eczema, this possibility is worth raising with your doctor.
Temporary Changes in Blood Eosinophils
Eosinophils are white blood cells involved in allergic and parasitic responses. Dupixent causes a transient rise in blood eosinophil counts, typically peaking around week four before drifting back to baseline or lower by week 24. The bump is modest in most people, and clinically significant symptoms linked to the eosinophil spike were rare across studies, occurring in only seven out of over 4,600 treated patients.19PubMed. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis The eosinophil rise does not appear to reduce the drug’s effectiveness.
Interestingly, a study of Japanese patients found that those who did develop significant eosinophil elevation were much more likely to also develop conjunctivitis, suggesting eosinophil counts might serve as an early warning marker for eye problems.20Drug Discoveries & Therapeutics. The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis In all cases, the eosinophil levels returned to normal on their own even while patients continued the drug, and nobody developed serious complications like heart or lung involvement from the elevated counts.
Joint Pain and Inflammatory Arthritis
Joint symptoms on Dupixent are an emerging concern, though still poorly quantified. One retrospective study suggested that nearly 5% of atopic dermatitis patients on Dupixent experienced at least some degree of inflammatory arthritis, but reviewers suspect this figure may be inflated or that most cases are mild enough to go unnoticed.21PubMed Central. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management When joint inflammation does occur, stopping Dupixent reliably resolves it, although severe cases can take six months to a year to fully clear after discontinuation. If you develop new joint swelling or stiffness after starting Dupixent, it is worth mentioning to your doctor rather than assuming it is unrelated, because this side effect responds well to early management.
Infection Risk
Because Dupixent dampens part of the immune system, a natural concern is whether it makes you more infection-prone. The reassuring answer from clinical trials is that it does not appear to increase overall infection rates. Serious infections and non-herpetic skin infections actually occurred more often in placebo groups than in Dupixent-treated groups in randomized trials.22PubMed Central. The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults One plausible explanation is that Dupixent reduces S. aureus colonization on the skin, which is itself a major source of infection in people with atopic dermatitis. A study found significant reductions in S. aureus within just three days of starting Dupixent, even before clinical skin improvement was visible.23PubMed Central. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
There is a theoretical concern about parasitic infections, because IgE and eosinophils, both suppressed or altered by Dupixent, play a role in fighting helminths (parasitic worms). Mouse studies have shown that removing IL-4 and IL-13 signaling impairs the ability to clear parasites.24PubMed Central. Parasitic (Helminthic) Infection While on Asthma Biologic Treatment: Not Everything Is What It Seems However, no helminth infections were reported in clinical trials of Dupixent.25World Allergy Organization Journal. Risks and safety of biologics: A practical guide for allergists If you live in or travel to areas where parasitic infections are common, it is worth discussing with your prescriber, but in typical clinical practice this has not been a real-world problem. A single case report documented herpes simplex encephalitis in a young child on Dupixent and concurrent topical steroids, but this was an isolated event with no prior history of herpes, and it remains unclear how much the drug contributed versus the steroids or simple bad luck.26PubMed Central. A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis
Safety in Children
Dupixent is approved for children as young as six months for atopic dermatitis and has been studied across pediatric age groups. The side effect profile in children mirrors what is seen in adults: conjunctivitis and injection-site reactions are the most common issues.27PubMed Central. The Application of Dupilumab to Pediatric Patients Aged 6–11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far In fact, children and infants on Dupixent in randomized trials had a lower proportion of treatment-emergent adverse events than those on placebo, and serious adverse events were also less common in the Dupixent group.28PubMed Central. The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults A one-year open-label extension study in children aged six months to five years confirmed a consistent safety profile with sustained effectiveness.29PubMed Central. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Pregnancy and Vaccines
For women who become pregnant or are considering pregnancy while on Dupixent, a systematic review and meta-analysis found no significant increase in miscarriage risk or congenital malformations compared to the general population.30Acta Dermato-Venereologica. Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis The caveat is that the data are still limited and come from relatively small studies, so the conclusions are not definitive. Most prescribers weigh the severity of the mother’s condition against the incomplete safety data when deciding whether to continue during pregnancy.
On the vaccine front, a randomized trial showed that Dupixent did not interfere with immune responses to vaccines in adults with moderate-to-severe atopic dermatitis.31PubMed. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis Unlike some immunosuppressants that require timing vaccines around treatment cycles, Dupixent does not appear to blunt vaccine effectiveness. You can get your flu shot, COVID booster, or other vaccines on your normal schedule.
How the Body Responds to the Drug Itself
Like all biologic drugs, Dupixent can trigger the body to produce anti-drug antibodies (ADAs). Across age groups, treatment-emergent ADAs appeared in up to roughly 2% to 16% of patients, with the highest rates seen in adolescents.32PubMed Central. Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis For most people, antibody development did not affect how well the drug worked or cause additional side effects. High-titer antibodies, which were the most concerning, occurred in fewer than 1% of patients and were the variable most associated with lower drug levels and loss of effectiveness. Even in those cases, titers often decreased and effectiveness improved with continued treatment. A single case of serum sickness was reported in a patient with high-titer antibodies. The practical takeaway is that if Dupixent seems to stop working after months or years, immunogenicity is one possible explanation worth investigating.
How Dupixent Compares on Tolerability
One way to gauge real-world tolerability is drug survival, the percentage of patients still on a medication after a set period. An analysis of daily clinical practice found that the 18-month drug survival rate for Dupixent was 70%, considerably higher than competitors: roughly 52% for abrocitinib, 48% for upadacitinib, 39% for tralokinumab, and 20% for baricitinib.33PubMed Central. Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice Drug survival reflects a mix of effectiveness and tolerability, so it is not a pure measure of side effects alone, but it does indicate that fewer people abandon Dupixent due to adverse events or lack of response than other systemic options for atopic dermatitis. The JAK inhibitors (abrocitinib, upadacitinib, baricitinib) carry their own side effect concerns including acne, blood count changes, and cardiovascular risk warnings that contribute to their lower survival rates.
When Side Effects Show Up in Darker Skin
Most dermatology research has historically enrolled predominantly lighter-skinned populations, which means the descriptions of drug reactions are often calibrated to how they appear in lighter skin. For Dupixent-associated head and neck dermatitis specifically, the rash can look quite different in people with more melanin. Instead of bright red patches, the rash may present as diffuse darker discoloration or violaceous areas that are harder to identify as drug-related.34PubMed Central. Recognizing Dupilumab‐Associated Head and Neck Dermatitis in Skin of Color: A Case Series If you have darker skin and notice any unexplained facial skin changes after starting Dupixent, bring it up with your dermatologist, even if it does not look like the photos you see online. Awareness of variable presentations is growing, but it is still easy for this side effect to be missed or misattributed to a flare of the underlying eczema.